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Human skin xenografted to mice with severe com-
bined immunodeficiency syndrome (SCID) was eval-
uated to determine the integrity and fate of human 
dermal mast cells. There was an approximately 3-fold 
increase in number of dermal mast cells by 3 mo after 
engraftment (p < 0.05). These cells were responsive 
to conventional mast cell secretagogues and were 
confirmed to be of human origin by ultrastructural 
characterization of granule substructure and by reac-
tivity for the human mast cell proteinase, chymase. 
CD1a+ Langerhans cells, also bone marrow-derived 
cells, failed to show evidence of concomitant hyper-
plasia, and increased mast cell number was not asso-
ciated with alterations in number of dermal vascular 
profiles identified immunohistochemically for hu-
C utaneous mastocytosis is characterized by (i) diag-nostically significant m ast cell (MC) hyperplasia within the dermis (Murphy, 1995); (ii) localization of MCs in intervenular interstitium in addition to more normal angiocentric loci (Walsh et a/, 1991); 
and (iii) phenotypic shifts in epidennal expression of MC growth 
factor or stem cell factor (SCF) (Longley eta/, 1993; Weiss eta/, 
1995). T he m echanism(s) responsible for these events in mastocy-
tosis and in M C hyperplasias unrelated to specific mastocytosis 
syndromes are poorly understood, in part beca use in vi·vo models 
that recapitulate human disease have not as yet been developed. For 
example, it remains unclear as to whether mastocytosis involves a 
defect intrinsic to MCs or rather to regulatory molecules in their 
microenviron m ent that govern their differentiation and prolifera-
tion (Longley, 1994). Moreover, some workers have hypothesized 
that mastocytosis is a form of cellular hyperplasia (Weidner and 
Austen, 1990), whereas others regard some forms of this disorder to 
show charactedstics of clonality (Mirowslci el a/, 1990; Longley eta /, 
1996). 
A recent model with promise for in vivo study of human 
cutaneous inflammation and neoplasia involves human skin xeno-
grafts (HSX) transp'lanted to mice with severe combined immune 
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man CD31. RT-PCR analysis demonstrated human 
but not murine stem cell factor (SCF; also termed 
mast cell growth factor, c-kit ligand) mRNA in xeno-
grafts. Epidermal reactivity for stem cell factor 
protein shifted from a cytoplasmic pattern to an 
intercellular pattern by 3 mo after engraftment, sug-
gesting a secretory phenotype, as previously docu-
mented for human cutaneous mastocytosis. The 
majority (>90%) of mast cells demonstrated mem-
brane reactivity for human SCF at the time points of 
peak hyperplasia. These data establish SCID mouse 
recipients of human skin xenografts as a potential itt 
vivo model for cutaneous mast cell hyperplasia. Key 
words: mastocytosis/stem cellfactorlxeuografts. J Invest Der-
rtratol 109:102-107, 1997 
deficiency syndrome (SCID) (Bosma et nl, 1983). Skin so trans-
planted maintains human fun ction and phenotype and may be 
manipulated experimentally over prolonged intervals of time. 
Using the SCID/HSX model, we and others have documented 
acand1olytic blister formation after systemic reconstitution with 
pemphigus lymphocytes Ouhasz et nl, 1993a), growth and invas ion 
of human melanoma cells Ouhasz et a/, 1993b), regulation of 
extracellular m atrix molecules and integrin adhesion receptors 
during wound healing Ouhasz et nl, 1993c) and reproduction of 
hum an lichenoid dermatitis (Christofidou-Solomidou et al, 1997) 
and delayed hypersensitivity reaction (Petzelbauer et nl, 1996). 
In the course of developing further the SCID/HSX model for the 
study of the inflammatory cascade in xenografted human skin (Y an 
et nl, 1993, 1994; Christofidou-Solomidou eta /, 1996), we observed 
increases in numbers of dermal MCs so that the xenografted skin 
eventually developed a stt.iking similarity to lesions of human 
cutan eous mastocytosis.' T he purpose of the present study was to 
characterize the xenografts in terms of (i) expression of the human 
MC phenotype; (ii) the kinetics of lesion formation; (iii) potentia] 
associated changes in related skin cell populations; and (iv) expres-
sion of SCF required for MC differentiation and proliferation. 
Our findings indicate that by 3 mo after xenografting of human 
skin to SCID mice , dramatic increases in dermal MC numbers are 
observed. These cells are of human phenotype an d maintain 
1 Christofidou-So lomidou M , Albelda SM, Murphy GF: A novel i11 11i11o 
model for mastocytosis: hyperpla~ ia of human dermal mast cells in skin 
xenograftcd to immunodeficient mice. J lt111est Dermatol 1 02:611, 1994 
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fea tures of cutaneous MC hyperplasia for up to 8 mo after 
engraftment, are responsive to conventional MC secretagogues, 
and are associated with expression of human SCF, which displays a 
secretory pattern identical to that previously documented in natu-
rally occm:ring human mastocytosis (Longley et al, 1993). T lus 
model therefore holds pronlise for further exploration of the causes 
and potential treatments for disorders characterized by abnonnally 
increased numbers of cutan eous MCs. 
MATERIALS AND METHODS 
Skin Transplantation The protocols for skin transplantation have b een 
described previously in de tail Qu.hasz et nl , 1993a; Yan el nl, 1993; 
Christofido u-So lomido u el al, 1996). Briefly, SC!D mice were obtained 
from a colony maintained at the Wistar htstitute Animal Facility in a 
pathogen- free environment. At 4-6 wk of age, the plasma of each mouse 
was tested for lgM production, and only fully immunodeficient mice were 
used for tissue transplantation. FuU thickness neonataJ fOreskins from 
elective circumcisions were c ut into two h<tlves, trinuned to a diameter of 
1- 1.5 em , and grafted onto the R.anks of the SCID mice in wound bed s 
prepared b y removing size-matched circular pieces o f mouse skin down to 
the fascia. T he human skll1 grafts were held in place by nonabsorbablc 
suture m ateria l and covered with dressing clipped to the dorsal skin of the 
m1imal by means of a surgical staple. The dressing was re moved after 1-2 wk 
and grafts were allowed to heal further. 
Induction of MC Degranulation Several known M C secretagogues 
were tested for their ability to induce human M C degranulation after 
intrndcnnal injection (see b elow). The substances used were: (i) morphine 
sulfate (\Vye th, Philadelpl:Ua, PA) used at 2 mM; (ji) substance P (5 mM) 
(Sigma C hen:U cal Inc ., St. Louis, MO); and (iii) compound 48/80 (Sigma) 
used at 0.5 mg per ml. Concentrations were derived from previous studies 
(Christofidou-Solomidou et a/, 1996). 
Administration of the secre tagogues was performed as follows: A skin 
graft on one side of each m o use was injected inttadermally with 50 J.Ll of 
endotoxin-free sa line conta.ining 2 mg bovine serum albumin per ml 
(Sigma) as a protein carrier plus coUoidal carbon (Sigma) to m ark the site of 
injectiou (contro l side) . T he skin graft on the contralateral side was injected 
with the secretagogue diluted in 50 J,Ll of endotoxin-free saline containing 
2 mg bo vine serum albumin per ml with colloidal carbon (experimental 
side) . All injections were admir:Ustered centrally within grafts using 28 gauge 
needles to nlinitnize tnnuna. 
Tissue Preparation Mice were sacrificed during monthly intervals over 
a 3-mo period, and a fo urth group designa ted as > 3 mo consisted of animals 
sacrificed from 4-8 mo after transplantation. Human skin xenografts w ere 
dissected from the animaJs, and the explants were cu t into smal ler pieces, 
oriented, placed in OCT compound, and snap-frozen for immuno histo-
chemical analysis or ttiaged and prepared for electron microscopy. A total of 
32 xenografts were studied and a minimum of four animals were sacrificed 
for each of the fmu: gro ups (1 , 2, 3, and > 3 rno).lnaddition , all groups we re 
compared to baseline vaJues for neonatal foreskin at the time of transplan-
tation (T = 0; .u = 4) . 
Cryomicrotomy and Immut10histochemistry Seria l sections of 6 J.Lrn 
thickness were c ut fro m frozen specimens, fixed in cold acetone, and stored 
at - 70°C . Prior to stainin g, sections w ere blocked w ith 5% sewm appro-
priate for the secondary antibo dy used and incubated with the primary 
antibody fo r 1 h at room temperature or overnight at 4°C. T he bound 
antibody was detected by use of an avidin-biotin-peroxidase complex 
(Vector Labs, DurliJJgame, CA) procedu re with 3-amino-9-ethyl carbazole 
as the chrornagen . 
lmmunoperoxidasc sta ining was performed as previously d escribed 
(Christofidou-Solomidou et nl, 1996) . No coumerstaining was used in order 
to increase sensitivity. T he following monoclonal antibodies were used for 
immunostaining: (i) mouse anti-lnnnaJl pla tele t endothe lia l cell adhesion 
m olecule-1 (CD31) (AMAC, Westbrook, ME); (ii) m o use anti-human 
SCF, (Genzyme, Cambridge, MA); (iii) mouse anti-human CD1a (Becton 
Dickinson, San jose, CA); and (iv) mouse an ti-HMB-45 (Biogenex, San 
l<..amon, CA) . The followiJ1g polyclonal antibodies were used: (i) goat-anti-
human SCF, (R&D Systems, Minneapo li s, MN) ; (ii) goat-anti mouse SCF . 
(R&D Systems); (iii) rabbit-anti S-100 (Biogenex, San Ramon, CA); and 
(iv) anti-human chymase raised in rabbit against human granule-specifi c 
serine protease chymase, donated by Dr. N. Schechter (Schechter et nl, 
1986) . Eacl1 antibody was titrated to obtain op timal expression with minimal 
b;rckground staining. Controls consisted of omission of the primary anti-
bodies and of substitutio n of p rimary antibody incubations with irrelevant 
controls i. e . , mouse l gG 1 antibody raised against an irrelevant antigen 
(Keyhole Limpet Hemocyanin) (Becton Dickinson, San Jose, CA), normal 
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rabbit l gG, and normal goat l gG Qackson lmmunoresearch , West Grove, 
PA) . 
Double Labeling lntmunofluo~escence Microscopy Sections were 
blocked and incubated with the m onoclonal primary antibody to human 
SCF raised in m o use and polyclonal human chymase raised in rabbit, 
followed b y Ruoresccntly labeled secondary antibodies using Texas Red ru1d 
fluorescein isothiocyanate as fluoroch romes (Accurate Scientific, Westbury, 
NY). As a positive conb·ol, single labeling with each antibody was 
performed on serial sections , and double nega tive contro ls were accom-
plished in w hich non-inm1une rabbit lgG was u sed instead of the chymase 
polyclonal antibod y, and mouse lgG 1 to an irrelevant antigen (Becton 
Dickinson) instead of the SCF m ouse monoclonal antibody. T he sections 
were viewed with an MRC - 600 con foca l fluorescent microscope (Bio-Rad 
Microscience, Hercules, CA). 
Electron Microscopy Selected biopsies d emonstrating hyperplasia were 
evaluated using transmission electron microscopy as described previously 
(Whitaker-Menezes et nl , 1995). Briefly , explants were fixed in Karnovsky's 
fixative (Karnovsky, 1965), wash ed , deh ydrated with a graded se1-ies of 
ethanol to propylene oxide, and embedded in epon. U ltrathin sections were 
cut on an LKB ultroto me Ill (LKB , Drornma, Sweden), contrasted with 
uranyl acetate followed by bismuth subnitrate, and viewed with a Hitachi 
H7000 e lectron microscope (Hitachi Instruments, Elmsford, NY). 
Re-verse Transcriptase-Polymerase Chain Reaction (PCR) Punch 
biopsies (6 mm) were taken ex l l i iJO fro m either excised skin xenografts 
following variable times of engraftm ent on the host animals (SCJD mice) o r 
from skins prior to transplantatio n representin g the baseline samples. T he 
biopsies were taken from the center of the xenografts to avoid the 
murine-human skin junctional regions. The epidermis was separated from 
the dermis by overnight inc ubation in a dispase solution (Collaborative 
Biomedical Produ cts, Bedford, MA) nr 37°C (Matsumu ra et nl, 1975). Tota l 
RNA was extracted fro m the epidermaJ and derm al explants as described by 
C hromszynski and Sacchi (1987). Complem entary DNAs were transcribed 
fro m total RNA with avian m yelo blastosis virus reverse tran scriptase, u sing 
rando m h exam ers as prime rs (2 picom o l per ml , Phru·macia LKB, Piscat-
away, NJ) as described by Longley ct a/ (1991 ). O ligonucleotide primers 
corresponding to specific sequences in human SCF eDNA and DNA 
amplification was performed as d escribed (Longley el. a/, 1993; Weiss et a/, 
1995). 
Gel electropltoresis and southern blotting of PCR products, probe 
labeling and hybridization, subclou.ing, and seque ncing were d o ne accord-
ing to Longley eta/ (1993) and Weiss et nl (1995). 
Statistics MCs were enumerated as ch ymase-positive cells/mrn2 witl1 the 
assistance of an ocular grid micrometer. Monthly interval data were 
gro uped and analyzed . Differences am on g groups were anaJyzed using an 
analysis of vat~ance {p < 0.05). 
RESULTS 
Human MCs Undergo Progressive Hyperplasia in Xeno-
grafts N eonatal foreskin prior to xenotransplantation contained 
45 ± 5 (mean ± SEM) human chym ase-positive MCs situated 
primarily abou t supel'fi cial derma] vessels (Fig 1A). These cells 
contained numerous , tightly compacted cytoplasmic granules that 
stained strongly for human chymase (murine MCs adjacen t to g raft 
anastomosis were nonreactive). During the first and second 
months, M Cs sh.ifted fiom a normal perivascular to a more diffuse 
interstitial pattern of distribution (Fig 1B-D). T he number of MCs 
gradually increased until > 3 mo after engraftment, when chy~nase­
positive cells increased to a maximum of 161 ± 23 cells/ mm- (p < 
0.05). Figure 2 summarizes the evolutionary changes in MC 
number at timepoints exa mined . T he human phenotype of the 
hyperplastic MCs was confirmed furthe r by conventional ultra-
structure, which demonstrated complex cytoplasnuc granules of 
characteristic human phenotype (Whitaker-Menezes et rl!, 1995) 
(Fig 3). These granules contain ed subcompartments composed of 
electron-dense amorphous zones, crystalline lattice, and scroll-like 
matrices. In contrast, MCs in adjacent murine skin were ch aJ·acter-
ized by typical diffusely homogeneous, electmn-dense granules. 
O ccasional cells exhibited prominent Golgi zones and small cyto-
plasmic progranules consistent with active granulopoiesis (Dvorak 
et a/, 1986) (Fig 3A). Evidence of human/ murine MC ch.im.erism 
was not observed within the human xen.ografts . 
In order to determine whether hyperplasia in volved bone mar-
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Figure 1. Immunohistochemical stain-
ing for human chymase-positive MCs in 
xenografts at varying timepomts after 
engraftment. (A) time 0; (B) 1 mo; (C) 3 
mo; (D) 4 mo. (D) is higher magnification of 
granulated mast cells in 4 mo xenograft; (V) 
represents dem1al vessels. Scale bars: (A-C) 







row-derived cells other than MCs, xenograft specimens wez·e 
evaluated immunohistochemically for COla. Although Langerhans 
cells persisted in xenografts at all timepoints, significant alterations 
in cell number were not observed. The values over an observation 
period of 4 mo ranged from 11 to 15 ± 3 COla-positive cells per 
linear mm of epidermis. In order to exclude the possibility that MC 
hyperplasia was related to angiogenesis within grafts , representative 
samples were stained for human CD31 (platelet-endothelial cell 
adhesion molecule-1). Vessel prof1les/mm2 actually decreased over 
time from baseline '(e.g., 67 ± 7 to 39 ± 12 vessels/mm2 at 8 mo) 
in all groups of xenografts harvested after 3 mo from time of 
transplantation. Stains for S-100 protein failed to reveal increased 
numbers of epidermal melanocytes at timepoints of MC hyperpla-
sia, and induction of HMB-45 on melanocytes was not observed 
(data not shown). 
Hyperplastic Human MCs Are Normally Responsive to MC 
Secretagogues Direct intradermal injection of MC secretagogue 
















0 1 2 3 >3 
Time/ Months 
Figure 2. Graphic representation of numbers of human chymase-
positive MCs/mm 2 after xenoengraftment. p < 0.05 for 3- and > 3-mo 
groups IICI"SIIS unrransplanted (T = 0), 1- and 2-mo groups. (En·or bnrs , 
SEM). 
,.: . . 
·~. 
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
-I. 
'I: 






• . ~ .. , ...J 
~ ...• 
"'I" f.' .• 
.. ' 
- - ~o 
_, 
-9 










" I :, -~ 'l'l···t- · 
-: -· 
at timepoints of peak MC hyperplasia (Fig 4A) resulted in rapid 
diminution of chymase staining by 30 min (Fig 4B). Degranulation 
was evidenced by marked reduction in cytoplasmic granule number 
and staining intensity, granule enlargement, and apparent discharge 
of granules into the pericellular matrix. Transmission electron 
microscopy further confirmed the effects of secretagogues, showing 
loss of granule density and internal substructure, merging of 
adjacent granule membranes, coalescence of granule membranes 
with the MC plasma membrane, and extrusion of granule contents 
into the extracellular space (Fig 4D) (Caufield et al, 1990; Kaminer 
et a/, 1991) . Control injections of saline failed to produce evidence 
of degranulation. 
Human SCF Synthesis Persists in Xenografts and SCF 
Immunoreactivity Shifts to a Membrane Pattern Reverse 
transcriptase-PCR analysis of xenografts selected at peak intervals 
of human MC hyperplasia demonstrated that human SCF mRNA is 
persistent in both epidermal and dermal explants of xenografts as 
359- and 275-bp bands (Fig SA). Mmine SCF mRNA, however, 
was not detected (Fig SB) in either epidermal or dermal graft 
components, although it was readily detected in control murine 
skin (data not shown). 
Immunohistochemical evaluation for SCF revealed a normal 
weak cytoplasmic pattern within keratinocytes at tin1e 0 (Fig 6A); 
3 mo after engraftment (Fig 6B), staining shifted to an intercellular 
pattern. Occasional dermal cells were also stained at this time. 
Confocal microscopy of preparations co-labeled for human chy-
mase and SCF (Fig 6C,E and 6D,F, respectively), demonstrated 
membrane-associated SCF coating chymase-positive dermal MCs 
at 3 mo after engraftment (Fig 6F) but not prior to tlus point (Fig 
6D). Antibodies to murine SCF failed to decorate cells expressing 
human chymase at any of the times examined (data not shown). 
DISCUSSION 
In tlus study, we demonstrate that human skin xenografted to 
immunodeficient mice undergoes progressive MC hyperplasia and 
that these cells express human granule proteinases and ultrastruc-
tural phenotype. Although these cells are increased in number and 
show an abnormal interstitial distribution pattern, they respond to 
conventional MC secretagogues. MC hyperplasia within xenografts 
appears to be relatively selective and is not associated ~ith similar 
increases in Langerhans cells or angiogenesis. Human, but not 
murine, SCF mRNA is demonstrable within xenografts, and im-
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munoreactive SCF protein is associated with keratinocyte and 
dermal MC membranes at times of the hyperplastic responses . 
The mechanism of MC hyperplasia in human skin/SCID xeno-
grafts may involve (i) induction of MC differentiation from 
agranular precursors within the dermis; (ii) local replication of 
differentiated MCs; or (iii) inhibition of MC apoptosis. Evidence 
ofGolgi-associated progranule formation with features similar to 
putative primitive MCs in human mastocytosis (Mirowski el a/, 
1990) and to developing MCs in vitro (Valent eta /, 1989) was 
documented, suggesting that at least some of the observed 
increases in MC number resulted from granulopoiesis. Because 
xenografts are divorced from circulating human MC precursors, 
granulopoiesis would necessarily derive from resident dermal 
monocytic cells induced to undergo local differentiation or 
division. Mature MCs rarely divide, although mastocytosis cell s 
have been documented to show m etaphase and S-phase activity 
(Tsai et a/, 1991). We did not note mitotic figures by routine 
microscopy or ultrastructure. 
An increase in MC number remarkably similar to that shown in 
the SCID/HSX model occur in inflammatory dermatoses as well as 
in adult human mastocytosis . ln the latter, this is associated with 
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Figure 3. Ultrastructural examination of 
human MCs in 4-mo-old xenografts. (A) 
MC with rectallglllar eHclosHre a11d inset defining 
prominent Golg.i zone (rectm-1gular eHclosure) 
and Golgi-associated progranule formation 
(~). (B) MC containing numerous mamre 
granules with intemal scroll s (reclaHgular euclo-
sure and inset) Scale bars: (A,B) 1 !Lm; (A iuset) 
0.25 !Lm; (B i11set) 0.5 M-m. 
alteration of expression of SCF (Longley ct a!, 1993). These 
alterations consist of a shift in epidermal SCF distribution from a 
constitutive cytoplasmic pattern to an intercellular pattern consis-
tent with secretion. In addition to promoting MC differentiation 
and replication, SCF is known to prevent MC apoptosis (lnemura 
et a/, 1994; Mekori and Metcalfe, 1995). Therefore, the gradual 
increase in MC numbers within the xenografts could also be the 
result of increased MC survival. Tritiated thymidine incorporation 
studies or iu situ labeling for endonuclease-mediated DNA frag-
ments (Gilliam et a/, 1996) could potentially clarify the mechanism 
leading to increased MC numbers in xenografts. 
Although human SCF redistribution and secretion may partially 
account for the MC hyperplasia in the present study, mela.nocytic 
hyperplasia or HMB-45 induction, as may occur locally at SCF 
il"tiection sites i11 vi.,,o {Galli ct al, 1993; Costa et al, 1996; Grichnick 
eta/, 1995), was not observed. Tlus could be the result of il1trinsic 
differences between human skin itl 11ivo and hmmm skin xenografts, 
differences in SCF concentration threshold necessary for MC 11ers11s 
melanocyte stimulation, or induction of as yet undefined factors 
that selectively influence MC kinetics. The reason for human SCF 
redistribution in xenografts is unclear. lt is possible that removal of 
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Figure 4. Response of 4-mo old xeno-
graft MCs to injected secretagogue, 
compound 48/80. (A) Chymase immunohis-
tochemistry, before (A) and after (B) stimttla-
tion. Ultrastructure before (C) and after (D) 
stimulation (~ in (D) indicate discharged 
granule contents). Scale bars: (A&B) 10 [.Lm; 
(C,D) 0.5 !Lm. 





Figure 5. Reverse transcr iptase-PCR detection of human (A) and 
murine (B) SCF mRNA in three epidermal a nd dermal explants 
from 3-nto-old xenografts. 
xenografts from factors in the human circulation that potentially 
inhibit SCF could also account for tlus finding, an d this possibility 
is being evaluated. Although con ttibution of murine SCF was 
excl uded by PCR analysis and immunolustochenlish·y, it remains 
possible that altered human SCF expression could relate to expo-
sure of human skin grafts to other factors derived fi:om the nutrient 
mu1;ne microcirculation. 
Figure 6. Immunohistochemical and confocal immunofluores-
cence evaluation ofhwnan SCF in xenografts at time 0 (A,C,D) and 
3 mo (B,E ,F) after transplantation. (A) and (B) represent epidermal 
immunohistochemical staining fo r SCF; (C) and (E) represent confocal 
immLmofluorescence stainin.g fo r MC chymase; (D) and (F) represent 
confocal immunofluorescence staining for SCF. Scale bars: (A ,B) 50 fLm ; 
(C- F) 10 fLm). 
T H E J OURNAL OF IN VESTIGATIVE DERMATOLOGY 
MCs have been implicated in the induction of angiogenesis 
(Meitunger and Zetter, 1992), and increased MC numbers are often 
documented in conditions in which blood vessels proliferate 
(Kessler et al, 1976) . Quantitation of vessel numbers associated with 
M C hyperplasia in human foreskin xenografts failed to reveal a 
significant angiogenic response in our model. Because normal MCs 
produce factors such as basic fibroblast growth factor and heparin 
known to provoke angiogenesis (Gruber et al, 1994), it is possible 
that the hyperplastic MCs in xenografts are deficient in these 
molecules. Alternatively, active and ongoing degranulation m ay be 
required for induction of a sigtuficant angiogenic response. Because 
we have shown the hyperplastic populations of MCs irt xenografts 
to be secretagogue-responsive (Christo£idou-Solonlidou et a/, 
1996), a model now exis ts to more critically address tlus important 
biologic issue . 
Recent data (Longley et al , 1996) indicate that M Cs in some cases 
of human mastocytosis are clonal, with perman ent phosphorylation 
and activa tion of the KIT receptor tyrosine kinase . Such cells are 
self-replicating and appear to escape normal regulatory m ech atusms 
of MC homeostasis. Accordingly, it will be important to now 
determine whether clonal and autonomous M C proliferation exists 
or is inducible in human skin xenografts, as appears to develop in 
naturally occurring human mastocytosis. 
In summary, we have developed a model for human cutan eous 
mast cell hyperplasia using neonatal foreskin xenografted to SCID 
mice. TI-lls system should provide useful information con cenung 
m echatusm s that govern MC kinetics and the chronic effects of 
increased M C numbers on the dermal and epidermal microenvi-
ronment. Therapeutic strategies such as topical corticosteroids 
(Lavker and Schechter, 1985) for the treatment of mast cell 
proliferative disorders may now also be tested and their mechanisms 
better understood . 
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